Concepedia

Author

Changli Wang

Tianjin Medical University Cancer Institute and HospitalORCID

Also Known As

Chang-Li Wang, Chang-li Wang, Changli Wang

53

Publications

5.3K

Citations

17

H-Index

32

Concepts

All Affiliations

Tianjin Medical University Cancer Institute and HospitalPeking UniversityZhejiang Cancer HospitalPeking University Cancer HospitalJiangsu Cancer Hospital
CW

About

Changli Wang is an author at Tianjin Medical University Cancer Institute and Hospital specializing in lung cancer, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

12

4.6K

2

Health Sciences

5

5

185

3

Cell Biology

2

2

43

4

Engineering

1

1

10

5

Molecular Medicine

1

1

10

Changli Wang

×

24

Publications

5.2K

Citations

17

H-Index

YearCitations

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen,

The Lancet Oncology

2011

4K

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang,

The Lancet Respiratory Medicine

2018

288

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen,

Journal of Clinical Oncology

2019

259

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

Leina Sun, Qiang Zhang, Huanling Luan,

Journal of Experimental & Clinical Cancer Research

2011

84

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).

Caicun Zhou, Yi‐Long Wu, Xiaoqing Liu,

Journal of Clinical Oncology

2012

79

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Wen‐Zhao Zhong, Hong‐Hong Yan, Ke‐Neng Chen,

Signal Transduction and Targeted Therapy

2023

74

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Yuankai Shi, Lin Wu, Xinmin Yu,

Cancer Communications

2022

53

China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

Yuankai Shi, Yan Sun, Jinming Yu,

Asia-Pacific Journal of Clinical Oncology

2016

44

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Xue‐Ning Yang, Hong‐Hong Yan, Jun Wang,

JTO Clinical and Research Reports

2021

34

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Caicun Zhou, Ziping Wang, Meili Sun,

Nature Cancer

2023

31

Page 1